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Abstract 
 
Low plasma HDL cholesterol (HDL-c) has been recognized as a biomarker of 
cardiovascular disease (CVD) and diabetes. Also, low HDL-c is one of the characteristics of 
metabolic syndrome (MetS).  
Objective: To assess whether low HDL-c and/or low HDL functionality are associated 
with higher risk for CVD in subjects classified with MetS.    
Methods: Forty-subjects with MetS (11 men /29 women, 52.4 ± 9.5 years participated in 
the study. Anthropometric data [weight, height, BMI, waist circumference (WC), blood pressure 
(BP)], fasting plasma biomarkers [lipids, glucose, liver enzymes: alanine aminotransferase (ALT), 
and aspartate aminotransferase (AST), plasma insulin, and glycosylated hemoglobin (HbA1c)], 
biomarkers of oxidative stress and inflammation, and biomarkers of antioxidants status 
[glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, and total antioxidant 
capacity (TAC)] were measured. Lipoproteins particles were measured to identify the size and 
number. Also, the functionality of HDL was further assessed by measuring plasma 
apolipoproteins, paraoxonase-1(PON-1) and serum amyloid A1 (SAA1). 
Results: Participants had a mean BMI of 32.3 ± 2.7 kg/m2 (29.8 – 39.3 kg/m2) placing the 
majority in the obesity category. In terms of MetS characteristics, all subjects (100%) fit the criteria 
for WC; 63% either had high systolic BP, high diastolic BP, or both; 70% were hyperglycemic; 
48% had elevated plasma triglycerides (TG), and 43% had low HDL-c. We divided the subjects 
into two categories, Low HDL-c (men < 40 mg/dL and women < 50 mg/dL) (n = 17) and Normal 
HDL-c (men ≥ 40 mg/dL and women ≥ 50 mg/dL) (n = 23). Those with Low HDL-c had higher 
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systolic BP (129.9 ± 9.7 vs 121.2 ± 14.2 mm Hg, p < 0.05), higher TG (166.6 ± 8.0 vs 115.5 ± 
56.8 mg/dl, p < 0.05), and lower TAC (1.23 ± 0.9 vs 2.09 ± 1.5 mM Trolox equivalents, p < 0.05). 
In addition, strong negative correlations were found between HDL-c concentrations and each of 
the following parameters: WC (r= - 0.418, p < 0.01), insulin (r=-0.413, p < 0.05) and ALT (r = -
0.324, p < 0.05). Lipoprotein data showed that large VLDL, medium VLDL, and small LDL 
particles were significantly higher in the Low HDL-c group (9.4 ± 6 vs 5.6 ± 4.4 nmol/L, p < 0.05), 
(25.1 ± 11.3 vs 15.8 ± 8.2 nmol/L, p < 0.01), (822.5 ± 283 vs 522.4 ± 288.2 nmol/L, p < 0.01), 
respectively. Both large and total HDL particles were higher in the Normal HDL-c group (8.2 ± 
4.1 vs 4.3 ± 1.9 µmol/L, p < 0.01), (37.5 ± 4.4 vs 30.8 ± 4.8 µmol/L, p < 0.01), respectively. Apo 
A-I was significantly higher in Normal HDL-c group (985.4 ± 274.2 vs 790.7 ± 188.1 mg/L, p < 
0.05). Also, Apo A-I was positively correlated with total HDL (r = 0.671, p < 0.01) and large HDL 
particles (r = 0.530, p < 0.01), respectively. PON-1 activity was significantly higher in the Normal 
HDL-c group (26.7 ± 14.1 vs 12.4 ± 16.1 U/ml, p< 0.05).  
Conclusion: These data suggest that in these men and women with MetS, measuring both 
HDL-c concentrations and HDL particles can provide important information about levels and 
functionality of the protective HDL. In regards to plasma HDL-c, subjects with Low HDL-c 
appeared to have higher risk for CVD including dyslipidemia, hypertension, and higher 
concentrations for more atherogenic lipoproteins. Further, TAC, Apo A-I and PON-1 activity were 
lower among this group. These results confirm that individuals with Low HDL-c and MetS have 
increased risk for CVD.  
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Chapter 1 
Introduction 
 
 Cardiovascular disease (CVD) is estimated to be the major cause of death with an 
estimate  of 31% deaths per year globally.1 CVD is a health concern that can occur by different 
modifiable risk factors including tobacco smoking, dyslipidemia, hypertension, and obesity. When 
there is an intake of excess energy coupled with physical inactivity, an epidemic of obesity 
increases affecting optimal health. Another health issue correlated with obesity that increases the 
risk factors of CVD is metabolic syndrome (MetS). In the United States, it has been estimated that 
nearly 35% of adults have MetS 2. This metabolic abnormality is defined by having three or more 
of these clinical parameters; central adiposity, high blood pressure, hyperglycemia, high plasma 
triglycerides (TG), and low HDL-cholesterol (HDL-c) concentrations 3. Another factor that can 
contribute to an increase of CVD risk is the high concentrations of LDL-cholesterol (LDL-c) 
4.These abnormalities can further increase an individual’s risk for both CVD and type II diabetes 
mellitus 5. Plasma low HDL-c as one of MetS criteria has been shown to have an inverse 
relationship with the risk for coronary heart disease (CHD), even at low LDL-c levels, below 70 
mg/dL 6. Observational studies have been estimated that for each increment of 1 mg/dL in HDL-
c, there is an approximate 2–3% reduction in CVD risk7,8. This relationship is thought to be due to 
the cardioprotective properties of HDL. The most known function of HDL is that it mediates efflux 
of cholesterol ester (CE) from peripheral cells and transfers the excess CE to the liver for excretion 
9, in a process called reverse cholesterol transport (RCT). Other cardioprotective properties of HDL 
are: 1) inhibition of the expression of endothelial adhesion molecules and its action as anti-
inflammatory agent; 2) antioxidative effects due to the association of HDL with several antioxidant 
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enzymes such as paraoxonase-1 (PON-1), glutathione peroxidase (GPx), and superoxide dismutase 
(SOD); 3) prevention of oxidized LDL (Ox-LDL) induced apoptosis; and 4) regulation of platelet 
adhesion10,11. The HDL particle has two main key properties, the first one is its ability to bind to 
receptors on both hepatic and non-hepatic cells such as; ATP-binding cassette transporter A1 
(ABCA1) and scavenger receptor B1 (SR-B1)12,13. Another key property is enhancing the 
responsible enzyme for esterification of free cholesterol to CE through apoA-1 components, which 
is known as plasma lecithin-cholesterol acyltransferase (LCAT) activity 14. HDL particles are 
highly heterogeneous in size, shape, density, cholesterol, phospholipids as well as apolipoproteins 
content11,15,16. Usually, in clinical settings, plasma HDL-c concentrations are measured as a 
predictor and an independent risk parameter for CVD16–18.  In contrast, recent data suggest that 
even with high HDL-c concentrations, the incidence of atherosclerosis is not reduced 17, and very 
large HDL particles may induce the cardioprotective properties of the functional HDL 18. 
Interestingly, in two large trials in high-risk groups, it was shown that the occurrence of cardiac 
events was significantly and inversely associated with raised HDL particle numbers but not plasma 
HDL-c concentrations 19, and high HDL particle numbers significantly reduced CHD death by 
around 50% 20. Therefore, measuring both the HDL-c concentrations as well as parameters for 
HDL functionality in high-risk populations such as individuals with MetS is of great of interest. 
The aim of the present study was to analyze whether HDL-c and/or HDL functionality are 
associated with additional biomarkers of CVD in subjects classified with MetS. For that, we 
hypothesized that subjects with MetS with low HDL-c will have a greater risk for CVD as 
determined by clinical biomarkers, than subjects with MetS and normal HDL-c.  
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                                                          Chapter 2 
Review of Literature 
 
2.1 Cardiovascular Disease 
 Worldwide, the prevalence of obesity nearly doubled between 1980 and 2008 with 
cardiovascular disease (CVD) remaining the second leading cause of death globally1. As reported, 
obese individuals have 3.5 times higher probability of having 3 risk factors for CVD and 2.4 times 
higher possibility of elevated plasma cholesterol1. There are an estimated 62 million individuals 
diagnosed with CVD in the U.S.21,22. It was estimated that 75% of patients with heart failure had 
a history of hypertension23. As reported, the exact cause of CVD is unknown but there are well-
known factors that increase the risk of CVD24. CVD risk factors can be categorized into two 
groups, nonmodifiable and modifiable risk factors. The nonmodifiable risk factors include those 
that we cannot control, such as age, gender, ethnicity, and family history. In contrast, the 
modifiable risk factors are those that we can control and manage, such as dietary intake, weight, 
abdominal obesity, smoking, high blood pressure (BP), and type 2 diabetes mellitus (T2D). 
Abdominal obesity is one of the CVD risk factors and also a biomarker of metabolic syndrome 
(MetS) that can be measured by calculating waist circumference (WC) and waist-to-hip ratio 
(WHR). The increase of visceral adipose tissue can promote insulin resistance, hypertension, and 
dyslipidemia25,26. As reported, after adjusting for age, each 1 cm increase in WC and 0.01 increase 
in WHR is associated with an increase of 2% and 5% respectively, of CVD27. In the Framingham 
Heart Study, 5,881 participants were followed up to evaluate the relationship between body mass 
index (BMI) and the incidence of heart failure28. Heart failure developed in 496 participants within 
14 years follow up, and data showed that the incidence of heart failure increased with the increase 
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of BMI in both genders28.  It was reported that for each increment increase of 1unit in BMI, the 
risk of heart failure was increased in men and women about 5% and 7%, respectively28. 
Hypertension is another risk factor of CVD and one of the MetS features. In the U.S., it was 
estimated that approximately 50 million individuals have hypertension21. The prevalence of 
hypertension and T2D was also increased with the increase of BMI28. Low plasma high-density 
lipoprotein cholesterol (HDL-c) level is an important risk factor of CVD as well as a MetS 
biomarker. Studies have been shown that low HDL-c concentrations are associated with increased 
mortality29,30. High levels of oxidized low-density lipoprotein (Ox-LDL ) and lipoprotein a [Lp 
(a)] are abnormal lipoprotein profiles associated with CVD in MetS31. It has been observed that 
obese individuals who met MetS criteria have higher levels of oxidative stress and inflammatory 
markers including tumor necrosis factor- (TNF-), interleukin 8 (IL-8), and C-reactive protein 
(CRP) than those without MetS 32. 
2.2 Metabolic Syndrome  
Metabolic syndrome is a condition with a combination of metabolic disorders that increases 
the risk of CVD. This condition leads to increasing the risk of heart disease by 2-fold and T2D by 
5-fold5. The prevalence of this disorder is increasing, and it was estimated to be 25% worldwide33. 
Different factors can contribute to the development of MetS such as excess body weight, physical 
inactivity, rich fat and carbohydrate diets that can contribute to central obesity and insulin 
resistance (IR)33. Young individuals with MetS can suffer from serious health complications in 
their later years, thus controlling this condition and reducing its prevalence should be the main 
goal. Weight loss, exercise and healthy diet seem to have the biggest effect on health and help to 
reduce MetS parameters. A common feature for MetS subjects is the excess body fat (especially 
visceral fat), studies have been shown that fat accumulated in the visceral area was associated with 
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hypertension, T2D, and atherogenic dyslipidemia26,34. Atherogenic dyslipidemia is characterized 
by increased triglycerides (TG) and low HDL-c. These abnormalities can accelerate the risk of 
CVD, especially in a high-risk group as MetS.  
2.2.1 Definition  
In history, the term (metabolic syndrome) is a debated topic. In 1975, a German researcher, 
Hermann Haller coined this term35. Also, in 1988, Gerald M Reaven described a phenomenon that 
occurs in individuals with coronary artery disease (CAD) that includes a combination of the 
following; IR, hyperglycemia, hyperinsulinism, hypertriglyceridemia, hypertension, and low 
plasma concentration of HDL-c, as Syndrome X. After that the interest to identify this 
phenomenon increased36. There were different criteria set out by different associations to define 
and diagnose this condition. The World Health Organization (WHO) was the first to define MetS 
criteria in 1988, as a presence of high insulin levels in addition to two of the following factors: 
abdominal obesity, hypertriglyceridemia and low HDL-c; hypertension, or microalbuminuria. In 
1999, the European Group for the Study of Insulin Resistance (EGIR) suggested that the term 
insulin resistance syndrome was more appropriate and modified MetS criteria to have high fasting 
insulin concentrations plus two other factors out of four: abdominal obesity; high TG and low 
HDL-c; high BP; or high fasting plasma glucose levels33. The cutoff of these factors was different 
than those used by WHO. Another association set a criterion of MetS and became the most 
common guidelines  was the National Cholesterol Education Program –Third Adult Treatment 
Panel III (NCEP:ATP III) in 2001, and defined MetS as the having three of the five clinical 
measurements which include high WC, high BP, high fasting glucose, hypertriglyceridemia, and 
low HDL-c3.   
2.2.2 Parameters of MetS  
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 According to NCEP: ATP III guidelines, there are five metabolic disorders and the 
presence of three of these features, will meet the definition of MetS. Abdominal obesity has a 
greater impact on health and can increase CVD risk factors37,38. Abdominal obesity as WC has 
cutoffs that are different based on gender. For males, WC must be equal to or greater than 102 cm 
(40 inches) to meet the guidelines. For females to meet WC criterion, it must be equal to or greater 
than 88 cm (35 inches). Dyslipidemia is characterized by higher TG and lower HDL-c 
concentrations. Greater than or equal to 150 mg/dL is considered to be high TG. The cutoff of 
HDL-c concentrations is also based on gender. Less than 40 mg/dL (1.0 mmol/L) for males is 
considered low HDL-c concentrations. For females, the cut-off point of HDL-c is less than 50 
mg/dL (1.3 mmol/L). Another clinical measurement, common among obese individuals with IR is 
high BP. The guidelines defined that having the systolic BP equal to or over 130 mm Hg and the 
diastolic BP equal to or over 85 mm Hg is a criterion of MetS. Obesity itself causes and aggravates 
IR which is linked to several CVD risk factors, such as hyperglycemia and T2D33. High fasting 
glucose or in another term hyperglycemia is common among obese individuals when insulin in the 
body cannot regulate glucose levels after a meal intake. Thus, this can lead to elevated plasma 
glucose remaining in circulation. The cutoff of fasting plasma glucose was modified in 2004 from 
greater than or equal to 110 mg/dL (6.1 mmol/L) to greater than or equal to 100 mg/dL (5.6 
mmol/L), in accordance with the American Diabetes Association’s updated standard of normal 
fasting glucose level39. 
2.2.3 Prevalence of Risk Factors  
 According to the National Health and Nutrition Examination Survey (NHANES) 2003–
2006 and NCEP:ATP III guidelines, the most prevalent of MetS criteria were central obesity 
(53%), hypertension (40%), and hyperglycemia (39%), and the least prevalent were 
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hypertriglyceridemia (31%) and low HDL-c (25%)40. There were differences in the prevalence of 
MetS risk factors by gender. As reported, males had a higher age-adjusted prevalence of 
hypertension, hyperglycemia, and hypertriglyceridemia whereas females had a higher age-
adjusted prevalence of central obesity and low HDL-c concentrations40. It seems that among 
females the prevalence of each risk factors was increased with age. For males, the prevalence of 
hypertension and hyperglycemia was increased with age, but for central obesity, 
hypertriglyceridemia, and HDL-c were no significant differences with age40. 
 Based on race and ethnicity, the age-adjusted patterns varied between groups. Among 
males, non-Hispanic whites and Mexican-Americans had a higher prevalence of 
hypertriglyceridemia and low HDL-c than non-Hispanic blacks40. Non-Hispanic white males had 
a higher prevalence of central obesity than non-Hispanic black males, but non-Hispanic blacks had 
a higher prevalence of hypertension than Mexican Americans40. For females, central obesity and 
hyperglycemia were more common among non-Hispanic blacks and Mexican Americans than non-
Hispanic whites40. Non-Hispanic blacks had the highest prevalence of hypertension, while 
Mexican Americans had the highest prevalence of low HDL-c and hypertrigleyceriemia40.  
When BMI increased, the prevalence of each of the five risk factors as well as the 
prevalence of MetS was increased for both genders40. Overweight males were more than 6 times 
and obese males were more than nearly 32 times as likely to meet MetS criteria than males with 
normal weight or underweight40. Among females, overweight was 5.5 times and obese was 17 
times more likely to meet this criterion than normal and underweight40. It was reported that 
between 2003–2004 and 2013–2014, there were no significant changes in childhood obesity 
prevalence, but among adults there was an increasing trend41. 
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As reported, males and females 40–59 years old were around three times more likely to 
meet MetS criteria than those of younger age40. 25% of non-Hispanic black males met the ATPIII 
criteria compared to 37% of non-Hispanic whites40. In contrast, both non-Hispanic black and 
Mexican American females were about 1.5 times more likely to meet MetS criteria than non-
Hispanic white40. 
2.3 Lipoproteins Overview  
 Lipoproteins are clusters of lipids associated with proteins and serve as transport vehicles 
for lipids in the lymph and blood. Typical lipoproteins consist of hydrophobic molecules with TG 
and cholesterols on the inside surrounded by hydrophilic phospholipids (PL) on the outside.  The 
plasma lipoproteins have major classes defined by density and size at which they are isolated. 
Chylomicron (CM), very low-density lipoprotein (VLDL), and there is the intermediate density 
lipoprotein (IDL), which is the transit form of VLDL conversion to low density lipoprotein (LDL), 
and there is HDL42.  
After dietary fat intake, CM are produced and secreted by the enterocytes into the lymph, 
and they require apo B-48. These chylomicrons are TG-rich particles with around 82% TG. In 
addition, CM have, cholesteryl esters (CE), PL, vitamins A and E in the core and a monolayer of 
PL, free cholesterol, and protein on the surface43. CM also have apo E, apo C-II and apo C-III that 
were acquired from HDL in circulation. After the action of the enzyme lipoprotein lipase (LPL), 
the CM particles become smaller and returns to the liver as chylomicron remnant43. Typically, CM 
density is 0.92 - 0.96 g/ml with diameter approximately 100-500 nm42. 
VLDL particles are made primarily in the liver and they require apo B-100 for secretion. 
Around half is TG, and they also have apo A-I, apo A-II, apo E, apo C-I, apo C-II, and apo C-III43. 
VLDL particle density is 0.95- 1.006 g/ml and about 30-80 nm in diameter42. During VLDL 
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circulation, TG is donated to extra-hepatic tissues by the action of LPL43. As the TG is removed 
from VLDL, IDL is formed and then converted to LDL43. IDL particle density is heavier than 
VLDL with about 1.019 g/ml and 25-50 nm in diameter42. High concentrations of plasma IDL are 
associated with increased risk of CVD44. 
 LDL is known as a cholesterol rich lipoprotein that contains only apo-B100, and can be 
removed by LDL receptor on the liver and extra-hepatic tissues43. LDL particle density is about 
1.029-1.063 g/ml and has different subclasses42. Elevated plasma LDL-c is a risk factor for the 
development of CVD31. LDL-c is positively correlated with CAD and CVD mortality in the 
presence of MetS condition20. The heaviest lipoprotein and the smallest one is HDL, which will 
be discussed below in more detail.   
2.3.1 HDL Composition and RCT 
As mentioned above, HDL has the highest density with 1.063- 1.210 g/ml, and the smallest 
size (15-20 nm). HDL can originate from both the liver and intestine as a nascent particle devoid 
of lipids but containing apo A-I. Discoidal HDL particles interact with ATP-binding cassette 
transporter A1 (ABCA1), which is located at peripheral tissues, then free cholesterol will be 
esterified by the action of the enzyme lecithin cholesterol acyltransferase (LCAT) to form the 
spherical −HDL. LCAT is activated by the major apolipoprotein in HDL, apo A-I13. Half of each 
HDL particle is composed of PL, unesterified cholesterol, TG and exchangeable apolipoproteins 
such as, apo A-I, apo A-II, apo E, apo C-I, apo C-II, and apo C-III43. The other half consists of 
proteins, and according to the proteomic studies, they discovered that more than 100 proteins are 
in HDL particles in addition to the apo As45. HDL particles play a critical role in transporting the 
excess cholesterol from the peripheral tissues to the liver for elimination46. This beneficial process 
is known as reverse cholesterol transport (RCT). RCT is inversely correlated with CVD in that it 
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plays an important role in modifying the formation and development of fatty plaques47. There are 
different HDL subclasses, nascent HDL, HDL2 (larger and less dense), and HDL3 (smaller and 
denser). Nascent HDL known as pre- HDL has low lipid content while -HDL (HDL2+HDL3) 
has high lipid content48.  
 RCT occur in three stages; extravascular, intravascular, and intrahepatic46. The first stage 
is cholesterol efflux from cell membranes and it is transported between cell membranes via the 
action of ABCA1, which is located on extra-hepatic tissues and generates structures that facilitate 
the interaction with lipoproteins. Thus, the HDL particles uptake the unesterified cholesterol as 
well as antioxidant substances such as, vitamin E, Lutein and Zeaxanthin via the action of apo A-
I in HDL particles and ABCA-1 on the intestine9. The second stage is the esterification of free 
cholesterol in HDL by the action of the enzyme LCAT, and some of the formed CE is transferred 
to CM and VLDL by cholesteryl ester transfer protein (CETP) while some will remain in the HDL 
core to increase its size and decrease the density9,46. HDL particles are taken up by the liver through 
two pathways. The direct pathway is through apo A-I, which is a ligand for hepatic scavenger 
receptor BI (SR-BI) where selective lipid uptake occurs, then the cholesterol is directed for biliary 
excretion. The indirect pathway is through hepatic LDL- receptor, and by the action of CETP, 
which facilitates the exchange of TG from the apo B containing lipoproteins (VLDL, LDL, CM) 
with CE from HDL9,43. The RCT is finalized by the biliary excretion46.  
 
2.3.2 HDL Health Benefits  
 
In addition to removing excess plaque lipids through the RCT process, HDL exhibits anti-
inflammatory properties through interactions with the vascular endothelium and circulating 
inflammatory cells43,49. HDL has antithrombotic and antioxidant properties and improves 
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endothelial function, as well as expression of inflammatory mediators43. HDL particles have an 
important capacity to carry antioxidants47. Abnormal HDL particles promote endothelial 
superoxide production and reduce nitric oxide (NO) bioavailability, thus, causing endothelial 
dysfunction, increasing BP  and increasing cellular inflammation50. In contrast, normal HDL 
particles have favorable effects on endothelial cell proliferation, and promote NO production49. 
Also, it has been shown that HDL has antiapoptotic functions for a number of cell types 
such as, smooth muscle cells, some leukocytes, pancreatic β cells, cardiomyocytes, and bone-
forming cells 43,49. Recent studies in humans suggest that HDL-c was inversely associated with 
CVD30,50. The Framingham Heart Study identified CVD risk factors such as low plasma HDL-c 
concentrations, which were associated with a higher mortality rate29. It has been estimated that for 
each increment of 1 mg/dL in HDL-c, the CHD risk is reduced by 2% - 3% in men and women, 
respectively7. In a 10-year prospective study of male employees, it was reported that the 
development of ischemic heart disease was significantly higher among males with low HDL2, and 
high levels of LDL, IDL, and small VLDL51. 
Despite previously mentioned HDL benefits, HDL particles can be modified to become 
dysfunctional and pro-atherogenic particles under certain conditions such as, obesity, MetS, and 
chronic inflammation30,52,53. HDL is considered an anti-atherogenic lipoprotein, but HDL levels in 
unhealthy individuals is sometimes less efficient. Obesity and MetS affect HDL particles and 
cholesterol, HDL become smaller in size and less dense, which will impair its anti-atherogenic and 
anti-inflammatory properties54,55. All the three HDL subclasses are involved in RCT. However, 
there were negative correlations between HDL2 (larger) and CVD
31,46. In addition, it has been 
suggested that HDL3 particles (smaller) may have greater protective effects than the larger 
particles56. This topic remains controversial.   
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2.3.3 HDL particles and HDL-c Measurements 
It is well known that plasma HDL-c concentrations are negatively associated with 
atherosclerotic CVD, especially CAD. HDL-c can be measured in plasma and serum. Previous 
clinical trials that aimed to raise  HDL-c by pharmacology drugs including fibrates, niacin, and 
CETP inhibitors have failed to show health benefits or to improve CVD biomarkers and reduce 
CVD mortality 57,58. However, previous studies indicate that HDL particles concentrations can be 
superior to HDL-c concentrations as a predictor of CVD59. Measurements of HDL particle number 
and size become an improved assessment of cardiovascular risk6. HDL constitutes a heterogeneous 
group of particles that differ in density, size, lipid composition, and apolipoprotein content, thus 
HDL can be fractionated into discrete subclasses by different techniques12. HDL separation can be 
done by charge as capillary isotachophoresis60, and HDL size by using one of the following: gel 
gradient electrophoresis separation61, Fast liquid chromatography, Ion exchange 
chromatography62, or Nuclear magnetic resonance (NMR) by proton spectroscopy. Gradient gel 
electrophoresis can separate HDL into two fractions on the basis of density, HDL2 (1.063-1.125 
g/ml) and HDL3(1.125-1.21 g/ml)
12. These particles can be further divided into sub-fractions, 
HDL2 into HDL2b (10.6 nm) and HDL2a (9.2 nm), and HDL3 into HDL3a (8.4 nm), HDL3b (8.0 nm), 
and HDL3c (7.6 nm)
12. NMR is a technique that quantifies the number and size of VLDL, IDL, 
LDL, HDL particles and expresses each as lipoprotein particle concentration and as an average 
particle size63. It quantifies more than 30 lipoprotein fractions that can be grouped into 10 
subclasses based on diameter: large VLDL (> 60 nm), medium VLDL (35–60 nm), small VLDL 
(27–35 nm), IDL (23–27 nm), large LDL (21.2–23 nm), medium LDL (19.8–21.2 nm), small LDL 
(18–19.8 nm), large HDL (8.8–13 nm), medium HDL (8.2–8.8 nm) and small HDL (7.3–
8.2 nm)63. 
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Methods for measurement of HDL sub-fractions as mentioned before and measuring HDL 
functionality may also be more effective in predicting CVD risk than measuring plasma HDL-c 
concentrations alone. It is suggested that future research should determine the remodeling of HDL 
particles in unhealthy conditions50. Obesity and MetS are conditions that alter HDL particles and 
reduce HDL-c concentrations64. There is evidence that the small HDL particles mostly seen in 
MetS are functionally defective56. Further, small HDL particles were observed along with CVD63. 
In contrast, large HDL particles are strongly inversely associated with CVD63. Among MetS, 
abnormalities of lipoproteins particles were observed64. However, the relationship between sizes 
and numbers of HDL particles and the MetS parameters have not been fully addressed.  
2.3.4 HDL Functionality  
During tissue injury, inflammation status will induce the acute phase in which the liver 
increases the synthesis of acute-phase protein, which is serum amyloid A (SAA) and its isoforms, 
1 and 214. It is known that proinflammatory cytokines including interleukin 1- (IL-1), interleukin 
6 (IL-6) and TNF-  play important roles in hepatic expression of SAA response to acute-phase65. 
Elevation of plasma SAA levels causes mainly HDL3 remodeling, by which SAA displaces apo 
A-I to become an apolipoprotein of HDL and may alter HDL metabolism and cholesterol 
transport14. SAA may also promote a pro-inflammatory and pro-atherogenic HDL through limiting 
its ability to promote RCT66. Another important marker that significantly associates with CHD and 
has impaired the antiatherogenic properties of HDL particles is apo C-III. These findings are based 
on an observational study, which analyzed HDL-apo C-III levels in patients with and without 
CHD67. Patients with CHD were on statin treatment. After adjusting of covariates, among CHD 
patients with statin, plasma HDL along with elevated plasma apo C-III, and even with elevation 
of HDL-c concentrations, there was remaining CVD risk among CHD patients67. Thus, SAA1 and 
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apo C-III are considered markers for dysfunctional HDL particles. In contrast, apo A-I, apo-E and 
Paraoxonase-1 (PON-1) are markers for functional HDL particles. Apo A-I is one of the major 
HDL apolipoproteins that is required for normal HDL biosynthesis. Higher levels of HDL-c have 
been shown to significantly reduce CVD risk and in particular higher levels of apo A-I were 
negatively associated with CVD risk16. PON-1 is an enzyme that is synthesized mainly in the liver 
and secreted into the blood where it associates with HDL particles68. PON-1 has atheroprotective 
effects including inhibition of excess cholesterol synthesis and promotion of cholesterol efflux. 
PON-1 has also, anti-inflammatory functions and raises antioxidant effects of HDL68. 
Paraoxonase-1, 2, and 3 have antiatherogenic properties including delayed pro-atherogenic 
oxidation of LDL and cell membranes to prevent atherosclerosis development69. It was reported 
that due to lower PON-1 activity the interaction with SR-B1 receptors was less efficient among 
CHD patients when compared it with healthy individuals70. Thus, HDL associated PON-1 protects 
against CVD through previously described mechanisms of the action of PON-1. 
2.4 Therapeutics  
  The primary goal of caring for individuals with MetS is to reduce the clinical 
atherosclerosis disease risk factors. First-line therapy should focus on the major risk factors, such 
as elevated LDL-c, reduced functional HDL-c, hypertension, and prediabetes. Individuals with 
MetS rarely have normal body weight and are physically active. Therefore, lifestyle modifications 
including decreases in body weight, increases in physical activity, or following anti-atherogenic 
diets could be the key emphasis in MetS management. According to the American Heart 
Association, the first line of therapy should be a healthy diet and increased physical activity to 
achieve weight loss71.  Studies have shown an improvement in serum cholesterol, TG, HDL-c, 
inflammatory markers, BP and IR72–74. In the last 50 years, studies have been focused on examining 
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the relationship between health and diet. Many studies assessed the role of different diets on health 
benefits and decreases in the risk for disease75.  
2.4.1 Energy-Restricted Diets  
 Energy-restricted diets are the most common dietary strategies for reducing excess weight 
and related comorbidities. There is a variety of options for planning and monitoring a reduced 
kilocalorie diet. While some strategies recommend energy reduction without restricted food types, 
others are using the exchange systems to plan energy and nutrient intake42. The exchange system 
that has the flexibility to choose the daily amounts of calories from an exchange list of foods was 
established by American Diabetes and American Dietetics Associations76. The main approach of 
choosing a weight management plan is to be based on nutrition and exercise principles, suitable 
for each individual based on their preferences to promote long-term lifestyle changes to reduce 
weight effectively and to teach meal planning skills 76. The common problem in weight loss plans 
is helping the individual to maintain the weight loss long-term, rather than follow hypocaloric diets 
for a specific period of time, and face the difficulties to follow the new dietary habits. For 
individuals who are overweight or obese, which is the case for most individuals with MetS, weight 
loss is an urgent step as it is associated with the improvement of the individual metabolic profile 
of MetS. Weight loss is associated with improvement of visceral obesity, high blood pressure, and 
high fasting glucose77.  
Further, weight loss can also improve the low-grade inflammation condition among 
individuals with MetS78. At the same time, body weight reduction is associated with the 
improvement in plasma glucose levels and IR. In studies done with diabetic overweight/obese 
subjects [The Look AHEAD (Action for Health in Diabetes), n= 5,145]  have shown that 5-10% 
loss of body weight can improve participant’s fitness level, reduce glycosylated hemoglobin 
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(HbA1c), and improve CVD risk factors, such as decreasing high BP, decreasing fasting glucose 
levels, increasing plasma HDL-c, decreasing LDL-c, and decreasing TG concentartions79. Also, 
there was an evidence that even small weight reduction (5-10%) can reduce CVD risk factors, and 
the guidelines recommend a 5-10% loss of weight as an initial goal to obtain health benefits80,81.  
2.4.2 Moderate/Low Carbohydrate Diet 
The Food and Nutrition Board, Institute of Medicine, and National Academies 
recommendations set an Acceptable Macronutrient Distribution Ranges for 18+ years old daily 
intake for both genders, the percentages range are 45–65, 10–35, 20–35 for carbohydrate (CHO), 
protein, and fat respectively. The amount vs quality of CHO intake is a controversial topic, some 
studies suggested that the CHO reduction has health benefits especially with great weight loss and 
improved lipid profile82–84, while others suggested that the quality of CHO as measuring with 
glycemic index (GI) is more important as the quantity. GI is a method that consists of a ranking 
on a scale from 0 to 100 for classifying CHO-containing foods according to the postprandial 
glucose response42. The consumption of high GI-CHO has been associated with hyperglycemia, 
IR, T2D, and hypertriglyceridemia85,86. These abnormalities are directly related to MetS.   
Moderate, low CHO diets are different on their CHO percentages, for moderate the CHO 
distribution can be around 40 to 55% of daily energy requirement. In two studies done with T2D 
subjects, moderate CHO intake (40%) has shown health benefits83,87. Low CHO intake can reach 
5-30% energy from CHO. Consumption of low CHO diets has shown benefits to decrease plasma 
TG, decrease small LDL, decrease inflammatory markers, and increase HDL-c. In addition, it has 
a role in reducing blood pressure and increasing weight loss88. When total fat is reduced, CHO 
intake is increased and healthy unsaturated fats are decreased 89. Although consumption of low-fat 
diets was associated with significant weight loss, CVD rates did not decrease89. After comparing 
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these two diets, it seems that low CHO diet had further health benefits for increasing HDL-c 
significantly with a decrease in phenotype B of LDL, which is the small dense LDL particles that 
are considered more atherogenic with high susceptibility to become oxidized due to short lag phase 
and greater concentrations of conjugated dienes76,90.  
In one study, researchers examined the effect of approximately 10% CHO daily intake on 
weight loss and MetS parameters. Their participants checked their ketone levels through urine tests 
for maintaining ketones production after following the carbohydrate-restricted diet (CRD)91. In 
contrast, high CHO intake has been linked with an increase in MetS numbers regardless of fat 
intake in males and with higher MetS risk among females that consumed high CHO and low fat24. 
For Asian subjects with MetS who had relatively low BMI and consumed low-fat diet and high 
CHO intake, the incidence of MetS and CVD was higher than in western countries92. These results 
may indicate that excess CHO intake, not fat intake is associated with MetS. In another study, 
subjects consumed 13% of carbohydrates for 12 weeks, and researchers observed a significant 
reduction in plasma lipoprotein (a) and a reduction in CRP and TNF-α, which are inflammatory 
markers93. These findings are important because they add to the benefits of CRD in lowering 
inflammatory markers and plasma cholesterol. In subjects with MetS, a study was conducted to 
compare between consumption of CRD (20-25% CHO) and consumption of the American Heart 
Association diet (50-55% CHO)73. The CRD group had large VLDL particles while medium and 
small LDL particles were decreased73. In addition, apo B levels were significantly decreased73. 
Many studies concluded that a reduced carbohydrate diet results in a spontaneous reduction in 
energy intake that may lead to weight and fat loss94. Although CHO restricted diets are high in fat, 
the absolute amount of total fat is usually unchanged; and it has been shown that the only nutrient 
that is increased or maintained is protein24,95,96.   
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2.4.3 Daily Egg Consumption  
Egg consumption is one of the dietary strategies that has been associated with changes in 
small LDL and HDL subclasses to a larger one, and that has a positive effect on reducing CVD 
biomarkers 64. Participants with MetS have followed CRD along with consumption of 3 whole 
eggs/day for 12 weeks, large VLDL, small LDL-c, small IDL lipoproteins and insulin resistance 
were improved, and HDL numbers and sizes were increased 64. Large VLDL carries more TG, and 
smaller LDL and IDL are prone to be easily oxidized. Whereas larger HDL is favorable because 
of their roles in the RCT. Also, intake up to 3 eggs/day showed an improvement in HDL-c in 
healthy subjects 97. For individuals with MetS, intake of 3 eggs/day along with CRD had benefits 
on lipid profile and were safe to consume 64. Egg contents that might have role in influencing 
HDL-c concentrations are phosphatidylcholine and dietary cholesterol98. Dietary phospholipid 
intake has been associated with the increase of HDL-c concentrations in human and animal 
studies99. Egg consumption also had a role in RCT, in which the serum cholesterol efflux capacity 
was increased in subjects with MetS98. Studies have shown that with egg intake, HDL particles 
and cholesterol levels were positively improved in healthy populations100,101 as well as in MetS64. 
These findings indicate that eggs may be considered as a functional food that can promote 
beneficial shifts in HDL composition, metabolism, and function in both healthy and MetS 
populations.  
Eggs contain carotenoids lutein and zeaxanthin, antioxidants that may protect against lipid 
oxidation102. In a study conducted in healthy populations, the consumption of 0, 1, 2, 3 eggs per 
day were evaluated101. Compared to no egg intake with the 1-3 eggs/day, large LDL and large 
HDL were increased101. Large particles of LDL are known to be the least atherogenic LDL 
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subfraction because they are less susceptible to modification and oxidation. Also, apo A-I and 
LCAT were increased with 1-3 eggs/day consumption while PON-1 activity was increased 
significantly with the intake of 3 eggs/day101.  
2.4.4 Mediterranean Diet  
 
In 1970, a researcher observed the lower incidence of CVD and certain types of cancer in 
some Mediterranean countries compared to the USA or Northern Europe and hypothesized that it 
was possibly due to the dietary habits of that population103. The Mediterranean diet (MedD) is a 
diet consisting of fresh fish and seafood (as a source of omega-3), a moderate consumption of dairy 
products, poultry and eggs and a high consumption of plant-based foods, such as fruit, vegetables, 
legumes, nuts and seeds, and whole grains. Nut intake is mainly high relative to other diets. In 
addition, the intake of extra virgin olive oil, as the main source of dietary lipids and as a source of 
monounsaturated fatty acids (MUFA) is a unique characteristic for this diet. Another characteristic 
is low frequency and amounts of red and processed meat intake104. Omega-3 and olive oil intake 
have been shown to protect against factors that increase CVD risk, such as its effect on weight,  in 
a follow-up of a large Spanish cohort [The SUN project, Seguimiento University of Navarra], high 
intakes of olive oil were not associated with increased risk of subsequent weight gain105. Also, 
adherence to the MedD has been shown to reduce BP, reduce dyslipidemia, increase insulin 
sensitivity, and reduce obesity (visceral obesity, which is a well-known CVD risk factor)74,75,106–
108. In addition, in the PREDIMED study, which was a multicenter, randomized, controlled, 
parallel-group clinical trial, that aims to test the efficacy of the traditional MedD as the primary 
prevention of coronary heart disease, a total of 800 subjects (55-80 years) at high CVD risk who 
followed the MedD with high consumption of nuts and extra virgin olive oil had reduced serum 
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concentrations of inflammatory markers109. Since subjects with MetS have a low-grade 
inflammation, the MedD has been shown to have health benefits and can reduce MetS metabolic 
disorders, and the MedD is a lifestyle-friendly diet that could be an easy lifestyle modification for 
the overweight/obese group. The 2013 report guidelines on lifestyle management from the 
American Heart Association/ the American College of Cardiology71, and the European Society of 
Cardiology110 all recommend the MedD as a prevention to reduce CVD risk.  
These types of diets can be the primary step to prevent and reduce CVD risk factors 
correlated with the presence of MetS. For that, lifestyle modification as dietary intervention and 
exercise are two important factors to reduce body weight and central obesity, which can be the key 
to prevent and solve this worldwide epidemic.  
2.4.5 Exercise 
 Lifestyle modification is an important tool to reduce the future occurrence of MetS, these 
changes should include both dietary intervention and increased physical activity. Diet is a crucial 
key to weight loss and improve CVD risk factors as well as the activity level. According to 
NHANES 2011-2014, the prevalence of low HDL-c was significantly higher among adults who 
did not meet the recommended physical activity guidelines (21.0%) than adults who met the 
guidelines (17.7%)111.  In a meta-analysis about dietary intervention and/or physical activity on 
MetS subjects the long-term, moderate to moderately vigorous intensity exercise, three to four 
times per week, HDL-c concentrations were increased by 1.8 mg/dL along with decrease in TG 
levels by 19 mg/dL, those results were observed on 20 randomized control studies112. Another 
meta-analysis about the effects of exercise on T2D subjects has been reported. Exercise types were 
either anaerobic, resistance or a combination of both, the inflammatory cytokines (CRP and IL-6) 
were decreased and leptin levels were improved significantly with aerobic exercise113. Studies 
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about the role of different types of exercise on subjects with MetS, such as aerobic exercise alone 
versus combination of different types of exercise are insufficient, and there is a need to investigate 
the role of different types of exercise on MetS parameters and whether they have different benefits 
on lipid profile, which has positive effects on MetS114. Also, adequate assessment of lifestyle 
modification is needed to clarify which aspects and what degree of lifestyle modification are best 
to resolve MetS.  
 In summary, increases in MetS parameters among individuals with excess body weight can 
increase risk for CVD and T2D. Both HDL-c and HDL particles can provide different benefits. 
HDL particles have atheroprotective properties including antioxidant and anti-inflammatory 
properties, improvements of endothelial function, and RCT process. HDL-c is a measurement that 
can give some information about HDL in the circulation. Low plasma HDL-c is one of the MetS 
markers and also an independent risk factor for CVD. Although pharmaceutical drugs such as 
niacin and statin have an effect to increase plasma HDL-c to higher levels, the prevalence of CVD 
and mortality did not change. Thus, measuring HDL functionality starts to gain attention in 
research. It is known that functional HDL particles are expected to increase cholesterol efflux, 
decrease inflammation, and decrease thrombosis. Some of the markers for functional HDL are apo 
A-I and PON1. On the other hand, dysfunctional HDL particles are expected to decrease 
cholesterol efflux, increase inflammation, and increase thrombosis. Both apo C-III and SAA1 are 
two markers for dysfunctional HDL. Both diet and exercise have an effect on plasma HDL-c 
concentrations and HDL particles. Therefore, controlling these two factors and measuring HDL 
functionality along with measuring plasma HDL-c could be important to undrstand the effects of 
lifestyle interventions.   
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Chapter 3 
Materials and Methods 
 
3.1 Study Design 
Data for this project was obtained from recruited subjects of a study conducted at the 
University of Connecticut1. This observational study included men and women, aged 32-70 years 
old, and classified with MetS. The study was approved by the University of Connecticut 
Institutional Review Board (IRB H14-278). All subjects signed a written consent form prior to 
joining the study. The study was registered at Clinicaltrials.gov, protocol # NCT02531334. 
Every subject that was accepted in the study underwent a screening evaluation to determine 
whether they classified for MetS. The screening involved anthropometric measurements including 
weight, height, waist circumference and BMI as well as plasma values for triglycerides (TG), 
HDL-c and glucose, and blood pressure (BP). 
3.2 Subjects  
Data were collected from 40 overweight and obese men (n=11) and women (n=29), 32-70 
years old who met the proper criteria. The MetS criteria were in accordance with the NCEP:ATP 
III definition2, which is having any 3 or more of the following 5 characteristics: BP ≥ 130/85 mm 
Hg (either number, or use of antihypertensive medications); plasma glucose ≥ 100 mg/dL; TG ≥ 
150 mg/dL, waist circumference (WC)  ≥ 102 cm for men or ≥ 88 cm for women, and HDL-c < 
40 mg/dL for men or < 50 mg/dL for women2. Subjects had no current or history of heart disease, 
stroke, diabetes, liver disease, cancer, severe infections or autoimmune diseases. Subjects with 
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MetS were classified into two groups according to their HDL-c concentrations; Normal HDL-c 
group (n=23), (men=6; women=17), and Low HDL-c group (n=17), (men=5; women= 12). 
*Normal HDL-c → men ≥ 40 mg/dL and women ≥ 50 mg/dL.                                                       
*Low HDL-c → men < 40 mg/dL and women < 50 mg/dL.                                                                 
3.3 Anthropometrics  
 Weight in kilograms (kg) was measured to the closest 0.1kg on a portable scale and height 
in centimeters (cm) was measured to the closest 0.5 cm on a stadiometer. Both weight and height 
were used to calculate body mass index (BMI) in kg/m2 as the following equation: BMI= weight 
(kg)/ height (m2). WC was assessed with a flexible measuring tape that was placed at the top of 
the iliac crest directly on the skin, and subjects were standing forward, feet together, with both 
arms hanging freely. WC were averaged from 3 readings to the nearest 0.5 cm3. BP was measured 
on the right arm using an Omron automated BP cuff (Omron HEM 7320-Z/ HEM 7131-Z, Lake 
Forest, IL, USA), with subjects sitting quietly for 1-3 minutes rest. BP was measured from an 
average of  3 readings taken by the same individual to account for variability4.  
3.4 Diet and Exercise Analysis  
Diet Records Assessment was conducted through the analysis of 3-day diet records 
completed by participants at baseline. Participants were given instructions on how to fill out the 
diet records. Nutrition Data Systems for Research software (NDSR; 2013), developed by the 
Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN, USA, was used to 
analyze the diet records8. Subjects completed a 3-day exercise records, and an average was 
calculated to use for analysis.  
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3.5 Blood Analysis 
After a 12 hour overnight fast, blood samples were drawn from each subject. A total of 40 
ml blood was collected from the antecubital vein into Ethylenediaminetetraacetic acid (EDTA)-
containing tubes to prevent coagulation. A sample of whole blood (1ml) was collected and frozen 
at -80 degrees Celsius for further analysis. Plasma was isolated by centrifugation at 2000 x g for 
20 minutes, and then 500 µl of plasma were used in Cobas c-111analyzer (Roche Diagnostics, 
Indianapolis, IN)5 to determine plasma lipids, glucose, liver enzymes and C-reactive protein 
(CRP). The remaining plasma was aliquoted and frozen at -80 degrees C° for further analysis.  
3.5.1 Lipid Analysis, Glucose, Glycosylated Hemoglobin (HbA1c), Liver Enzymes, C-Reactive 
Protein and Insulin  
Plasma total cholesterol (TC), TG, glucose, HDL-c, CRP, liver enzymes alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), and HbA1c were all determined 
using an automated clinical chemistry analyzer (Cobas c-111, Roche Diagnostics, Indianapolis, 
IN) via enzymatic reactions and photometric detection method5. Plasma LDL-c was calculated by 
the Friedewald equation: LDL-c= TC - HDL-c - (TG/5). This equation was based on measurements 
of plasma TC, HDL-c and TG in mg/dL, and become the standard method for LDL-c assessment 
because it is simpler than direct assays6. Plasma insulin was measured by an ELISA kit (Crystal 
Chem, Elk Grove Village, IL), which utilizes a specific antibody immobilized onto the 96- 
microplate wells and an antibody labeled with HRP enzyme. After incubation and washout steps 
the substrate solution was added followed by incubation in the dark for 15 minutes. Then the stop 
solution was added and the insulin levels of samples were measured according color intensity by 
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using a BioTek Synergy 2 Multi-Mode Microplate Reader with Gen5 Software (BioTek 
Instruments, Inc.) at wavelength 450nm7. 
3.5.2 Lipoproteins Size and Subfractions  
Fasting plasma was used to determine total lipoprotein particle number, size, and 
concentration using proton nuclear magnetic resonance (NMR) spectroscopy. NMR analysis was 
performed on 400 MHz NMR analyzer (LipoScience, Inc., Raleigh, NC)8. This technique can 
quantify the size, number, and concentration of lipoprotein particles expressed each as an average 
particle size or as lipoprotein particle concentration by a specific methyl signal9. The NMR 
simultaneously quantifies >30 lipoprotein fractions that are grouped into subclasses based on size. 
The lipoprotein subtractions were: small VLDL (27–35 nm), medium VLDL (35–60 nm), large 
VLDL (>60 nm), IDL (23–27 nm), small LDL (18–19.8 nm), medium LDL (19.8–21.2 nm), large 
LDL (21.2–23 nm), small HDL (7.3–8.2 nm). medium HDL (8.2–8.8 nm), and large HDL (8.8–
13 nm).  
3.5.3 Apolipoprotein Analysis  
Plasma apolipoproteins (apo A-I, apo A-II, apo B, apo C-II, apo C-III, and apo E) were 
quantified simultaneously by using a commercially human apolipoprotein multiplex assay kit 
(EMD Millipore, Billerica, MA) and analyzed by a Luminex MAGPIX analyzer (Luminex 
Corporation, Austin, Texas, United States)8. This procedure quantifies apolipoproteins in plasma 
using antibody-immobilized fluorescent dye labeled microspheres.   
3.5.4 HDL Functionality: PON1 and SAA1 
 Plasma PON1 activity was measured by a commercial fluorometric assay kit (BioVision, 
Inc, Milpitas, CA)10. This assay kit enables rapid measurement of PON1 activity through utilizing 
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a fluorogenic substrate that is converted into a highly fluorescent product (Ex/Em = 368/460 nm). 
Plasma samples, standards, positive and negative controls were added to black 96- fluorescence 
microplate wells.  The reactions were carried out according to the manufacturer’s instructions and 
the fluorescence levels were measured in kinetic mode for 60 minutes at 37 degrees Celsius by 
BioTek Synergy H1 Microplate Fluorescence Reader with Gen5 Software (BioTek Instruments, 
Inc.; Winooski, VT, USA). Calculations were made by using the following formula:                   
 Sample PON1 Activity = 𝑩/ Δ𝑻×𝑽 = pmol/min/ml = U/ml 
Where: B = the amount of metabolite produced, calculated from the standard curve (in pmol) 
           ΔT = the linear phase reaction time t2 – t1 (in minutes) 
             V = the volume of sample added to the well (in ml)  
                                                                                                              
Plasma SAA1 was measured by a ProcartaPlex Multiplex Immunoassay Human assay kit 
(Invitrogen, Vienna, Austria). This kit is used to perform quantitative multiplexed protein 
measurements in plasma samples using magnetic beads technology from Luminex to enable the 
simultaneous detection of SAA111. Samples and standards were added to the black 96- microplate. 
The protocol was followed according to the manufacturer’s instructions and the samples were 
diluted 1:200.  After the last incubation at room temperature on a plate shaker and the addition of 
reading buffer to all wells, the analysis was done by using a Luminex MAGPIX analyzer (Luminex 
Corporation, Austin, Texas, United States). 
3.5.5 Plasma Inflammatory Biomarkers   
 Plasma tumor necrosis factor- (TNF-), monocyte chemoattractant protein-1 (MCP-1), 
Interleukin (IL)-6 and IL-8, were measured by use of the LINCOplex: Multiplex Biomarker 
Immunoassay for Luminex MAGPIX Technology (Luminex Corporation, Austin, Texas, United 
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States). This technique uses the fluorescently labeled microsphere beads with antibodies to each 
individual cytokine12.  
3.5.6 Plasma Antioxidant and Oxidative Stress Biomarkers and Oxidized LDL  
 Plasma glutathione peroxidase (GPx), superoxide dismutase (SOD), total antioxidant 
capacity (TAC), and catalase were measured using commercially available kits (Cayman Chemical 
Company, Ann Arbor, MI). The activity of GPx was measured indirectly by a coupled reaction 
with glutathione reductase 13. SOD activity was determined by measuring the extent of superoxide 
radical generation by xanthine oxidase and hypoxanthine 14. TAC was measured by assessing the 
oxidation extent of 2,2’-Azino-di-3-ethylbenzthiazoline sulfonate14. Catalase activity was assessed 
by measuring formaldehyde production in the presence of hydrogen peroxide. Thiobarbituric acid 
reactive substances (TBARS) were assessed as a marker of lipid peroxidation by using a 
commercially available kit (R&D Systems, Minneapolis, MN)15 and a BioTek Synergy 2 Multi-
Mode Microplate Reader with Gen5 Software (BioTek Instruments, Inc.) for measuring the 
absorbance. 
Ox-LDL was measured using a solid phase capture sandwich enzyme linked 
immunosorbent assay (ELISA) technology5. The 96-microwell plate to which the samples and 
standards were added was coated with antioxidized LDL antibodies. After the washout step, HRP 
enzyme was added and then TMB substrates. TMB was catalyzed by HRP to produce a blue color 
that changed into yellow after adding the stop solution. The intensity of the yellow color is directly 
proportional to the concentration of Ox-LDL on the plate. The Ox-LDL concentrations were 
measured by using a BioTek Synergy 2 Multi-Mode Microplate Reader with Gen5 Software 
(BioTek Instruments, Inc.) at wavelength: 450nm.  
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3.6 Statistical Analysis  
 Statistical analysis was performed using SPSS version 25 statistical software for Windows 
(SPSS, Inc., Chicago, IL). Significance was defined as p < 0.05. Data values were represented as 
mean ± standard deviation (SD). Un-paired t tests were used to determine significant differences 
between the groups in plasma lipids, apoproteins, lipoprotein subfractions, plasma inflammatory 
biomarkers, plasma antioxidant biomarkers and anthropometric measurements. Pearson 
correlations were used to evaluate positive and/or negative relationships between HDL level and 
lipoprotein size and number.  
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Chapter 4 
Results 
 
4.1 Baseline Characteristics 
 To assess whether low HDL-c concentrations are associated with the biomarkers of 
cardiovascular disease, 40 subjects who classified with MetS according to the NCEP:ATP III 
criterion were divided into two groups based on plasma HDL-c concentrations into Normal HDL-
c [men ≥ 40 mg/dL and women ≥ 50 mg/dL] and Low HDL-c [men < 40 mg/dL and women < 50 
mg/dL]. Subject’s diet intake and exercise records are shown in Table 1. There were no significant 
differences between the two groups in any of the analyzed nutrients including macronutrients, 
types of fat, glycemic index, fiber or carotenoids. Similarly, there were not significant differences 
in terms of minutes exercise per day in both groups. Subject’s age ranged from 32 -70 years old 
and their anthropometric measurements are displayed in Table 2. Based on BMI values, the 
majority of subjects were in the obese category (n=27). WC on average was 106.9 cm for the 
Normal HDL-c group and 110 cm for the Low HDL-c group. Plasma HDL-c on average was 61.4 
mg/dL in subjects with Normal HDL-c and 38.5 mg/dL in subjects with Low HDL-c. Systolic 
blood pressure (BP) as well as TG were different between groups. The Low HDL-c group had 
significantly higher systolic BP and TG than Normal HDL-c group (p < 0.01). Other MetS 
parameters (WC, fasting glucose and diastolic BP) were not different between groups. A negative 
correlation was found between HDL-c and waist circumference (WC) (r= -.0418, p < 0.01) and 
between HDL-c and insulin (r= - 0.413, p < 0.025) as presented in Figure 1 and Figure 2, 
respectively. In addition, a positive correlation was found between TG and insulin values as 
presented in Figure 3.  
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Table 1. Diet and exercise records in Normal HDL-c and Low HDL-c groups 
 
- Data presented as Mean ± SD 
 
 
 
 
 
Parameter Normal HDL-c  Low HDL-c  P value 
Total Energy (kcal) 2051.4 ± 891.6   2025.1 ± 472.3   0.913 
Carbohydrate (%) 38.3 ± 9.0  40.4 ± 6.7  0.408 
Protein (%) 17.2 ± 2.9  18.3 ± 3.8   0.315 
Fat (%) 41.2 ± 8.6   39.1 ± 7.4   0.428 
SFA (g/day) 30.3 ± 12.2   31.4 ± 15.1  0.797 
MUFA (g/day) 39.7 ± 41.8   32.9 ± 11.9  0.523 
PUFA (g/day) 21.3 ± 17.5   19.5 ± 6.4   0.676 
Trans Fatty Acids 
(g/day) 
2.5 ± 2.3 2.1 ± 0.94  
0.250 
Cholesterol (mg/day)  311.0 ± 139.7  311.7 ± 193.2  0.990 
Total Fiber (g/day) 21.8 ± 14.8    24.1 ± 10.3  0.590 
Soluble Fiber (g/day) 6.7 ± 2.2  7.7 ± 2.4 0.224 
Insoluble Fiber (g/day) 14.9 ± 13.5   16.4 ± 8.5  0.700 
Glycemic Index 57.7 ± 6.1   56.6 ± 5.6   0.577 
Glycemic Load 101.7 ± 44.2  106.4 ± 34.5  0.720 
β-Carotene (μg) 3423.4 ± 3255.9  3886.2 ± 3430.1  0.666 
α-Carotene (μg) 577.7 ± 1045.2  645.8 ± 924.4   0.832 
Lycopene (μg) 6522.7 ± 7733.0   3959.8 ± 4016.2   0.221 
Lutein + Zeaxanthin 
(µg/day) 
2390.8 ± 2108.9  3830.7 ± 4787.4  
0.206 
Exercise 
(minutes/week) 
36.7 ± 29.8   53.8 ± 50  
0.185 
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Table 2. Anthropometrics, blood pressure (BP), plasma total cholesterol (TC), triglycerides 
(TG), HDL-c, LDL-c, plasma glucose, plasma insulin and glycosylated hemoglobin (HbA1c) in 
Normal HDL-c and Low HDL-c groups 
 
- Data presented as Mean ± SD 
 
 
 
Parameter Normal HDL-c Low HDL-c P value 
Age (years)  53.3 ± 9.4 51.2 ± 9.8 0.492 
Weight (kg) 88.6 ± 17.3  93.6 ± 14.6   0.341 
BMI (kg/m2)  32 ± 4.1  32.7 ± 3.3 0.563 
 
WC (cm) 
114.2 ± 15.5 (men) 
 
113.6 ± 11.5 (men) 
 
0.948 
104.4 ± 8.3 (women) 
  
108.5 ± 9.5 (women) 
 
0.231 
WC (cm) 
Both genders 
106.9 ± 11.2 109 ± 10.1 0.381 
Systolic BP (mm Hg) 121.3 ± 14.2 129.9 ± 9.8 
0.028 
 
Diastolic BP (mm Hg) 84.8 ± 7.1 83.1 ± 9.1 0.507 
TC (mg/dL)  187.4 ± 36.3 178.6 ± 30.8 0.426 
TG (mg/dL)  115.5 ± 56.8 165.7 ± 80.7 0.026 
 
HDL-c (mg/dL) 
47.2 ± 5.1 (men) 
 
31.6 ± 3.8 (men) 
 
0.000 
66.5 ± 18.6 (women) 
 
41.4 ± 3.8 (women) 
 
0.000 
        HDL-c (mg/dL) 
Both genders 
61.4 ± 18.2 38.5 ± 5.9 0.000 
LDL-c (mg/dL) 102.7 ± 31.7 107 ± 29.6 0.662 
Glucose (mg/dL) 106.2 ± 10.1  105.1 ± 9.9 0.733 
Insulin (pmol/L) 45.6 ± 29.9  60.3 ± 29.1 0.141 
HbA1c (%)  5.6 ± 0.45  5.6 ± 0.58 0.815 
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Figure 1. Negative correlation between HDL-c concentrations and waist circumference (WC) 
 
 
 
Figure 2. Negative correlation between HDL-c concentrations and insulin 
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Figure 3. Positive correlation between TG levels and insulin 
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4.2 Lipoprotein Size and Subfractions  
 VLDL, LDL and HDL size as well as VLDL, LDL and HDL subfractions were assessed 
using NMR spectroscopy. Numbers, size, and total of each lipoprotein. Total VLDL particles in 
Normal HDL-c group and Low HDL-c group are presented in Figure 4. Large and medium sizes 
of VLDL particles were significantly higher in the Low HDL-c group [large: p= 0.028; medium: 
p= 0.005] as presented in Figure 5. In addition, total LDL particles in Normal HDL-c group and 
Low HDL-c group are presented in Figure 6. As shown in Figure 7, large LDL particles, which 
are the less atherogenic lipoprotein were lower in the Low HDL-c group while small LDL particles, 
which are known to be the most atherogenic lipoprotein were higher when compared with Normal 
HDL-c [ large LDL: p= 0.012, and small LDL: p= 0.002]. Total HDL particles were lower 
significantly in the Low HDL-c group compared to the Normal HDL-c group (p =0.000), as shown 
in Figure 8. In addition, HDL particles distributions are presented in Figure 9. Large HDL 
particles were lower significantly in the Low HDL-c group compared to the Normal HDL-c group 
(p <0.05). LDL and HDL particles as measured in nanometers were lower in the Normal HDL-c 
group compared to the Low HDL-c group as presented in Figure 10.  
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Figure 4. Total VLDL particles (nmol/L) in Normal HDL-c and Low HDL-c groups 
 
 
 
 
Figure 5. Concentrations of large, medium and small VLDL (nmol/L) in Normal HDL-c and 
Low HDL-c groups 
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Figure 6. Total LDL particles (nmol/L) in Normal HDL-c and Low HDL-c groups 
 
 
 
Figure 7. Concentrations of large and small LDL (nmol/L) in Normal HDL-c and Low HDL-c 
groups 
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Figure 8. Total HDL particles (µmol/L) in Normal HDL-c and Low HDL-c groups 
 
 
 
Figure 9. Concentrations of large, medium and small HDL (µmol/L) in Normal HDL-c and Low 
HDL-c groups 
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Figure 10. Lipoprotein size (nm) in Normal HDL-c and Low HDL-c groups 
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4.3 Apolipoproteins (apo) Distribution based on Plasma HDL-c  
 The distribution of apo A-I, apo A-II, apo C-II, apo C-III, apo E, and apo B in the plasma 
was assessed using a human apolipoprotein multiplex assay kit to compare apolipoproteins 
distribution between the two groups as presented in Table 3. Apo A-I was significantly lower in 
Low HDL-c group compared to the Normal HDL-c group. None of the other apolipoproteins were 
statistically significant between groups. There was positively correlation between Apo A-I and 
large HDL particles that presented in Figure 11. Also, there was a positive correlation between 
Apo A-I and total HDL in Figure 12. When waist measurement increased, apo A-I is that mainly 
present in HDL particles was decreased that was presented as a negative correlation between WC 
and apo A-I in Figure 13. There was a positive correlation between TG and apo C-III that 
presented in Figure 14. 
Table 3: Apolipoproteins distribution based on plasma HDL-c  
- Data presented as Mean ± SD 
 
 
 
 
Parameter Normal HDL-c  Low HDL-c  P value 
Apo A-I (mg/L) 
 
985.4 ± 274.2 790.7 ± 188.1 0.019 
Apo A-II (mg/L) 
 
599.0 ± 159.4  586.4 ± 173.9 0.813 
Apo C-II (mg/L) 
 
243.4 ± 161.1 283.8 ± 212.5 0.497 
Apo C-III (mg/L) 
 
474.7 ± 274.1 520.1 ± 330.8 0.639 
Apo E (mg/L) 
 
106.2 ± 60.4  125.3 ± 62.9 0.339 
Apo B (mg/L) 
 
1707.1 ± 704.4  1908.8 ± 598.0  0.346 
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Figure 11.  Positive correlation between large HDL and Apo A-I 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Positive correlation between total HDL and Apo A-I 
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Figure 13.  Negative correlation between WC and Apo A-I 
 
 
 
 
Figure 14.  Positive correlation between TG and Apo C-III 
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4.4 HDL Functionality [PON-1 and SAA1] 
 
 PON-1 was assessed as a functional marker for HDL particles, its activity was measured 
by using a fluorometric assay kit. PON-1 activity values for both groups are presented in Figure 
15. PON-1 values were significantly higher in the Normal HDL-c compared to the Low HDL-c 
group (p= 0.022). In Figure 16, a positive correlation was found between PON-1 and total HDL. 
SAA1 was measured as a functional marker for HDL. In Figure 17, SAA1 values are presented 
for both Normal HDL-c group and Low HDL-c group. There were no significant differences 
between groups. In addition, there was a positive correlation between SAA1 and the inflammatory 
marker CRP that is presented in Figure 18.  
 
Figure 15. Paraoxonase-1 (PON-1) activity in Normal HDL-c and Low HDL-c groups 
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Figure 16. Positive correlation between PON-1 and total HDL 
 
 
 
 
Figure 17. Serum Amyloid A1 (SAA1) in Normal HDL-c and Low HDL-c groups 
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Figure 18. Positive correlation between CRP and SAA1 
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4.5 Inflammatory Markers  
 
Mean values for inflammatory markers [liver enzymes [alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST)], C-reactive protein (CRP), tumor necrosis factor- (TNF-
), monocyte chemoattractant protein-1 (MCP-1), and Interleukin (IL)-6 and IL-8] categorized for 
Normal HDL-c and Low HDL-c groups are presented in Table 4. None of the inflammatory 
markers were significantly different between groups. There was a negative correlation between 
HDL-c and ALT, which is one of the liver enzymes as shown in Figure 19.                                                                                    
Table 4. Inflammatory markers and liver enzymes in Normal HDL-c and Low HDL-c groups 
- Data presented as Mean ± SD 
Figure 19. Negative correlation between HDL-c and ALT 
 
 
 
 
 
 
 
 
 
Parameter Normal HDL-c  Low HDL-c  P value 
AST (U/L) 25.0 ± 6.1 26.2 ± 7.4  0.598 
ALT (U/L) 29.2 ± 10.7 29.6 ± 10.8  0.915 
CRP (mg/dL) 0.39 ± 0.39  0.31 ± 0.29 0.456 
TNF- (pg/mL)  6.2 ± 2.4 6.9 ± 3.9  0.508 
MCP-1 (pg/mL) 129.6 ± 66.6  122.2 ± 29.0 0.676 
IL-6 (pg/mL)  5.5 ± 0.78  5.99 ± 1.3  0.185 
IL-8 (pg/mL) 9.7 ± 10.3  7.9 ± 1.2  0.479 
r = - 0.324; p < 0.05 
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4.6 Antioxidants and Oxidative Stress Biomarkers and Oxidized LDL 
Plasma antioxidant and oxidative stress biomarkers [thiobarbituric acid reactive substances 
(TBARS), total antioxidant capacity (TAC), superoxide dismutase (SOD), plasma glutathione 
peroxidase (GPx), catalase (CAT)] as well as Ox-LDL are presented in Table 5. Total antioxidant 
capacity (TAC) was significantly higher in subjects with Normal HDL-c (p = 0.044) when 
compared to subjects with Low HDL-c. Other markers were not different between groups. 
Table 5. Antioxidants and oxidative stress biomarkers and oxidized LDL (Ox-LDL) in Normal 
HDL-c and Low HDL-c groups 
- Data presented as Mean ± SD 
 
 
 
 
 
 
 
Parameter Normal HDL-c  Low HDL-c  P value 
TBARS (μM) 
 
 0.16 ± 0.03  0.14 ± 0.03 0.087 
TAC (mM Trolox equivalents) 
 
 2.1 ± 1.5 1.2 ± 0.9 0.044 
SOD (U/mL) 
 
 2.3 ± 1.2  1.9 ± 1.2 0.361 
GPx (nmol/min/mL) 
 
 150.6 ± 23.9  141.5 ± 20.2  0.220 
CAT (nmol/min/mL) 
 
19.4 ± 11.7 17.2 ± 7.0 0.507 
Ox-LDL (ng/ml)  201.2 ± 14.5  212.6 ± 62.9  0.405 
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Chapter 5 
Discussion and Conclusion  
 
Metabolic Syndrome is a well-defined condition that increases the risk of CVD and T2D1. 
We assessed data collected from 40 individuals, 11 men and 29 women classified with MetS, by 
separating subjects into two categories based on HDL-c concentrations. This classification allowed 
us to determine whether low HDL-c is associated with additional biomarkers of CVD such as a 
high atherogenic dyslipidemia, a low grade of inflammation, and high oxidative stress biomarkers. 
In addition, this classification allowed us to understand the importance of measuring HDL 
functionality along with measuring plasma HDL-c to identify risk factors of CVD among 
participants with MetS.  
In this study we found that individuals with MetS and low HDL-c had higher TG, systolic 
BP, WC, and lower total antioxidant capacity than those with normal HDL-c. We also found that 
subjects with low HDL-c had a more atherogenic lipoprotein profile as assessed by higher 
concentrations of large VLDL, medium VLDL and small LDL. In terms of HDL functionality, we 
found that Apo A-I was positively correlated with both large HDL and total HDL particles. Also, 
Apo A-I was significantly lower in Low HDL-c group. Further, we found a diminished HDL 
functionality as determined by PON-1 activity.    
5.1 Metabolic Syndrome Parameters 
  Obesity is a crucial characteristic that increases the metabolic complications among 
individuals with MetS. Increases in weight and BMI are strongly associated with health issues for 
example: CVD, insulin resistance, T2D, hyperlipidemia, and hypertension2. Unhealthy diets and 
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physical inactivity are the common habits that accelerate obesity rate3. These two factors were 
shown in the subject’s diet and exercise records as high caloric intake, high saturated fatty acids 
intake, and low physical activity level. As demonstrated in this study and based on BMI categories, 
all subjects in this study were either overweight or obese, and more than half of them fit the obese 
categories including obese I [BMI= 30.0 – 34.9 kg/m2], obese II [BMI= 35.0 – 39.9 kg/m2]. The 
main problem with obesity is fat distribution and fat deposition4. Excess adipose tissues are 
associated with altering adipokines production, and that might increase the risk of insulin 
resistance as well as CVD4. Particularly, visceral adiposity is strongly correlated with insulin 
resistance4. Visceral adiposity can be measured through measuring the waist circumference area. 
WC was the most common MetS parameter determined in this population. Palaniappan et al. have 
shown that each 11 cm increase in WC is associated with an adjusted 80% increased risk of 
developing MetS condition5. In addition, according to the NCEP:ATP III, abdominal obesity is 
known to be an essential characteristic of MetS6. All participants in the current study met the WC 
requirement, in addition to two other markers of MetS diagnosis criterion. Another marker of MetS 
is high BP. The mean of systolic BP was significantly increased among Low HDL-c group. 
Elevated BP is known to be one of the CVD risk factors, and it was estimated that 5 mm Hg 
reduction in systolic BP would result in overall reduction of 14% in stroke mortality and 9 % in 
CHD mortality4.  In a study done on subjects with MetS, approximately 25.1% had high TG levels 
(TG > 150 mg/dL)2. In the present study, 48% of subjects had high TG levels. Plasma TG 
concentrations were significantly different between the two groups. The Low HDL-c group had 
higher TG values than subjects in the Normal HDL-c group. Elevated TG values are strongly 
correlated with increased risk of CVD. Insulin resistance results either from a genetic defect or 
obesity, and it may lead to elevation in TG and fasting glucose levels as well as BP and reduction 
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of HDL-c5, as demonstrated in this study. Elevated TG was positively correlated with insulin 
levels. In addition, measuring fasting glucose in obese subjects is an important predictor for other 
CVD risk factors, and it is one of the MetS parameters. Since the majority of the current subjects 
fit the obese category, 48% of them had hyperglycemia that placed them in MetS condition. Since 
subjects were divided into two groups based on their HDL-c values, HDL-c concentrations were 
significantly different between the two groups and between genders in each group. Low HDL-c 
values were always linked to be a risk factor of CVD and T2D7. Observational studies have shown 
that each decrease of 1-mg/dL in HDL-c concentration is associated with a 2% - 3% increased risk 
of CVD8,9. In contrast, normal HDL-c concentrations are recommended and linked to be a 
protective parameter against diseases. 
5.2 Lipoprotein Particles  
Recently, interest has shifted from not only focusing on the quantity of HDL particles but 
also focusing on HDL quality9. HDL exhibits antiatherogenic mechanisms including its role in the 
RCT process, anti-inflammatory, antioxidant and antithrombotic functions, all of which could 
contribute to the protection against atherosclerosis10. These functions may be disrupted when HDL 
particles become dysfunctional. Therefore, measuring lipoprotein particle size and number is an 
important aspect to better understand lipoproteins metabolism11. Lipoproteins particles that are 
considered atherogenic for example: large VLDL, medium VLDL, and small LDL particles are 
present in increased numbers in the MetS populations12. The number of these particles has been 
shown to be positively associated with CVD risk. In the current study, NMR method was used to 
measure number and size of different lipoprotein particles. This method not only quantifies the 
overall lipoprotein particles, but also measures different sizes for each lipoprotein. The NMR 
method is well known as a useful and accurate method that helps to link specific lipoproteins to 
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CVD11. Our findings indicate that MetS subjects with Low HDL-c had significantly increased 
numbers of large and medium VLDL as well as of small LDL compared to subjects with Normal 
HDL-c while large LDL particles were lower in numbers compared with the Normal HDL-c group. 
Large LDL particles are known to be less susceptible to oxidation and subendothelial retention 
than small LDL particles13. Calculating LDL-c did not give us enough information about the whole 
picture of the LDL particles. Thus, measuring LDL particles subfractions provided important 
information in regards to which particles were dominant as well as it allowed us to compare these 
particles across subjects with MetS based on the HDL-c values. That also allowed us to draw a 
conclusion that low HDL-c is associated with more atherogenic lipoprotein profiles. In contrast, 
large HDL particles were significantly higher among subjects in the Normal HDL-c group also 
indicating a more efficient RCT in this group and in addition negative correlation have been found 
between HDL particles numbers and CVD14.  
5.3 Apolipoproteins 
In regards to apolipoproteins, Apo A-I was significantly higher in the Normal HDL-c group 
compared to the Low HDL-c group. Apo A-I is mainly present in HDL particles and higher levels 
of this apolipoprotein were inversely associated with CVD risk. According to the current data, 
there was a positive correlation between Apo A-I and both large HDL and total HDL. Also, an 
inverse correlation was found between WC and apo A-I. As mentioned previously, obesity 
particularly the increase in WC, has effects on well-being, and is considered an independent risk 
factor for CVD. HDL-c has been shown to improve through weight loss including decreases in 
WC15. Our findings indicate that when WC increased apo A-I was decreased suggesting that HDL 
might improve with decreases in weight and WC. Even though subjects in the Normal HDL-c 
group has higher values of HDL-c, that does not necessary means the presence of functional HDL 
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particles. Thus, measuring HDL functionality markers are important to provide a better view of 
the atheroprotective lipoprotein HDL. HDL particles may have proatherogenic modifications that 
lead to increase the risk of chronic diseases instead of being protective. Dysfunctional HDL result 
in decreases in cholesterol efflux and increases in inflammation and thrombosis. There are some 
markers indicative of HDL dysfunctionality, such as, apo C-III and SAA1. In the current study, 
apo C-III was positively correlated with TG levels. It is known that apo C-III has proinflammatory 
and prothrombotic effects9. HDL functionality can be evaluated through measuring apo A-I, and 
PON-1. In the current study, Apo A-I was significantly lower in the Low HDL-c group in 
compared to the Normal HDL-c group.  
5.4 HDL Functionality [PON-1 and SAA1] 
 The enzyme that associates with HDL particles and has atheroprotective functions is PON-
1. Lower PON-1 activity is related to CHD, and the MetS condition has been shown to reduce the 
enzymatic capacity of PON-116.  In the current study, plasma PON-1 was measured in kinetic mode 
by fluorometric assay kit. Subjects with Normal HDL-c had significantly higher PON-1 activity 
compared to subjects with Low HDL-c. Increased PON-1 activity is a marker for HDL 
functionality, and Normal HDL-c group had higher numbers of large HDL particles and HDL-c 
concentrations. In addition, PON-1 activity levels were positively correlated with total HDL, and 
with large HDL particles. Thus, large HDL particles seem to be functional in Normal HDL-c 
group. One study has shown that PON-1 activity levels are significantly lower in MetS subjects16. 
That finding was also demonstrated in the present study.  
 Another marker for HDL functionality is SAA1. SAA1 is an apolipoprotein of HDL in the 
acute-phase, which causes HDL remodeling and dysfunctionality17. It was documented that SAA1 
plays a major role in lipid metabolism because it can alter the distribution of cholesterol in the 
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lipoproteins, and can be act as a lipid acceptor for ABCA1 but its impact on lipid metabolism 
remains incompletely understood17. SAA1 for this study was measured in plasma samples, and 
there was no statically difference for SAA1 between the two groups. SAA1 increases in acute 
phases, and we found that SAA1 values were positively correlated with the inflammatory marker 
CRP. It is well established that elevated CRP levels are associated with the increase of WC, BMI 
and hyperlipidemia along with MetS condition4. That was also documented in the current study.     
5.5 Inflammatory and Antioxidants Biomarkers 
Individuals with MetS are often obese, and obesity is known to be associated with low-
grade inflammation and increased oxidative stress 18. Studies have shown that MetS has 
independently linked with low-grads inflammation and increased oxidative stress biomarkers. 
Also, plasma TNF- is positively associated with body weight, WC, and TG, while it is negatively 
associated with HDL-c4. Liver enzymes are commonly used as indicators for liver functions. 
Studies have shown that individuals with MetS have higher values of liver enzymes [ALT and 
AST] compared with healthy populations19. Our findings indicate that HDL-c values in this 
population were negatively associated with the liver enzyme ALT. While there was no significant 
difference in inflammatory markers between groups, total antioxidant capacity was significantly 
different. Because antioxidants are mostly carried in the body through HDL, the increase of HDL 
will help in the transportation of these antioxidants throughout the body as, was demonstrated in 
this study. TAC values for our subjects were significantly higher among subjects in the Normal 
HDL-c group. On the other hand, lipid peroxidation markers such as Ox-LDL are increased in 
MetS20. Both lipid peroxidation markers when they are at high levels, are significantly correlated 
with CVD in subjects with MetS20.  
5.6 Conclusions 
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 These data suggest that in these men and women with MetS, measuring both HDL-c 
concentrations and HDL particles can provide important information about levels and functionality 
of the protective HDL. In regards to plasma HDL-c, subjects with Low HDL-c appear to have 
higher risk for biomarkers associated with CVD such as, high TG levels, systolic BP, and WC and 
lower antioxidant capacity than subjects with Normal HDL-c. We measured lipoproteins size and 
number and we found that large and medium VLDL and small LDL particles were higher in Low 
HDL-c group compared with Normal HDL-c group. In contrast, large LDL, which is the one 
known to be less atherogenic compared to small LDL, was significantly higher in Normal HDL-c 
group. For that, it appears that in the MetS condition, having normal HDL-c concentrations, the 
most common atherogenic sizes of lipoproteins are lower compared to subjects with Low HDL-c. 
Apo A-I was positively correlated with total HDL and large HDL particles. In addition, we were 
able to measure HDL functionality through measuring PON-1. PON-1 was positively correlated 
with total HDL but there was no correlation found between PON-1 and large HDL particles, that 
might due to the fact that we did not have enough subjects to find significance.  
5.7 Limitations and Future Directions  
 In the current study, we were able to measure both HDL-c and HDL particles in 40 subjects 
with MetS. Measuring both of these parameters can provide more information about the 
importance and possible relationships with increased CVD risk factors. There were 11 men and 29 
women in this study. For that, one possible limitation can be the unequal numbers of each gender, 
which limits further analysis to be done based on gender type. Another limitation could be the 
overall number of subjects in each group based on HDL-c concentrations, and this might be one 
possible reason that many markers were not statistically significant. We were able to measure 
inflammatory markers such as, TNF- CRP, and IL-6 that are used to determine the inflammatory 
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levels as well as T2D and CVD risk factors. However, we did not measure leptin, which is an 
adipokine that is involved in the regulation of satiety and energy intake4. Development of obesity 
can cause increased levels of plasma leptin. Leptin is positively correlated with adiposity that can 
cause leptin resistance, which is common in obese and MetS indivduals4. Also, elevated plasma 
leptin levels not only affect satiety and metabolism but also have an effect on BP and increase the 
peripheral vascular resistance, for hyperleptinemia, which is considered an independent CVD risk 
factor4. Another important marker that we did not measure is adiponectin. Adiponectin is 
negatively associated with WC, TG, fasting insulin, and blood pressure. Further,  adiponectin is 
positively associated with HDL in which it can enhance PON1 production4. Thus, it will be 
interesting to look to these markers and to check different possible correlations in subjects with 
MetS. Also, adiponectin expression is reduced by the increase of TNF-. Since individuals with 
MetS have increased inflammatory markers and possibly high TG, BP and low HDL-c 
concentrations, measuring adiponectin will provide interesting information in this high-risk group. 
Another important point as a future direction is to assess expression for oxidative stress and 
inflammation related genes in Normal HDL-c groups and Low HDL-c group. One of the 
limitations of the fluorometric kit used for PON-1 measurement is requires EDTA containing tube. 
Thus, we faced a technical issue during this measurement. This is one limitation that can be a 
considered for future studies. It would be useful to utilize another kit such as ELISA and/or using 
serum PON-1 to measure all PON-1 isoforms to better understand HDL functionality. Another 
future direction is to look at gender and ethnicity as it relates to MetS, HDL-c, and HDL particles 
in the data analysis. It has been indicated that gender and certain ethnicities can be different in 
regards MetS parameters and HDL functionality. Therefore, it will be interesting to examine these 
factors and how they are different between groups.  
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